Latest Insider Positions


GROENHUYSEN WILHELMUS CM is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
NVCR / NovoCure Chief Financial Officer 108,218

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-08-02 NVCR / NovoCure S -1,790 108,218 -1.63 35.05 -62,740 3,793,041 -1.65
2018-08-02 NVCR / NovoCure S -5,336 110,008 -4.63 35.00 -186,760 3,850,280 -4.85
2018-08-01 NVCR / NovoCure S -100 115,344 -0.09 35.05 -3,505 4,042,807 -0.09
2018-08-01 NVCR / NovoCure S -200 115,444 -0.17 35.025 -7,005 4,043,426 -0.17
2018-08-01 NVCR / NovoCure S -941 115,644 -0.81 35.00 -32,935 4,047,540 -0.81
2018-07-27 NVCR / NovoCure S -1,100 116,585 -0.93 37.05 -40,755 4,319,474 -0.94
2018-07-27 NVCR / NovoCure S -6,095 117,685 -4.92 36.60 -223,077 4,307,271 -5.18
2018-07-27 NVCR / NovoCure S -34,385 123,780 -21.74 35.20 -1,210,352 4,357,056 -27.78
2018-07-27 NVCR / NovoCure S -17,437 158,165 -9.93 34.44 -600,530 5,447,203 -11.02
2018-07-27 NVCR / NovoCure S -3,710 175,602 -2.07 33.86 -125,621 5,945,884 -2.11
2018-07-06 NVCR / NovoCure A 1,191 179,312 0.67 17.255 20,551
2018-05-14 NVCR / NovoCure S -280 178,121 -0.16 30.25 -8,470 5,388,160 -0.16
2018-05-14 NVCR / NovoCure S -200 178,401 -0.11 30.225 -6,045 5,392,170 -0.11
2018-05-14 NVCR / NovoCure S -200 178,601 -0.11 30.20 -6,040 5,393,750 -0.11
2018-05-14 NVCR / NovoCure S -1,772 178,801 -0.98 30.15 -53,426 5,390,850 -0.99
2018-05-14 NVCR / NovoCure S -4,927 180,573 -2.66 30.10 -148,303 5,435,247 -2.73
2018-05-14 NVCR / NovoCure S -100 185,500 -0.05 30.075 -3,008 5,578,912 -0.05
2018-05-14 NVCR / NovoCure S -3,590 185,600 -1.90 30.05 -107,880 5,577,280 -1.93
2018-05-14 NVCR / NovoCure S -10,008 189,190 -5.02 30.00 -300,240 5,675,700 -5.29
2018-05-11 NVCR / NovoCure S -2,700 199,198 -1.34 30.025 -81,068 5,980,920 -1.36
2018-05-11 NVCR / NovoCure S -6,693 201,898 -3.21 30.00 -200,790 6,056,940 -3.32
2018-05-01 NVCR / NovoCure S -30,470 208,591 -12.75 27.58 -840,363 5,752,940 -14.61
2018-02-23 NVCR / NovoCure S -13,351 239,061 -5.29 19.828 -264,724 4,740,102 -5.58
2018-02-22 NVCR / NovoCure M 43,334 252,412 20.73 21.55 933,848
2018-01-09 NVCR / NovoCure S -31,132 209,078 -12.96 21.0194 -654,376 4,394,694 -14.89
2018-01-08 NVCR / NovoCure A 310 240,210 0.13 15.045 4,664
2018-01-04 NVCR / NovoCure S -26,264 239,900 -9.87 21.0293 -552,314 5,044,929 -10.95
2018-01-03 NVCR / NovoCure S -2,404 266,164 -0.90 21.00 -50,484 5,589,444 -0.90
2018-01-03 NVCR / NovoCure S -200 268,568 -0.07 21.025 -4,205 5,646,642 -0.07
2017-07-05 NVCR / NovoCure A 2,484 268,768 0.93 6.673 16,576
2017-01-06 NVCR / NovoCure A 3,156 266,284 1.20 6.673 21,060
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of GROENHUYSEN WILHELMUS CM include the following: Ambrogi Michael J., Avista Capital Partners (Offshore) II, L.P., Avista Capital Partners (Offshore) II-A, LP, Avista Capital Partners II GP, LLC, Avista Capital Partners II, L.P., Bierly Rick, Bradshaw Paul, Burkoth William T., DOYLE WILLIAM F, Danziger Asaf, Entrepreneurs Fund General Partner Ltd, Entrepreneurs Fund LP, FUTRELL STEVE, GRANOFF MICHAEL D, Gibbs Thomas Edward, Goldan Keith A., HELTON SANDRA L, HILLEMAN JERYL L, Hung David, JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, LEUNG GABRIEL, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Madden Martin J., Mahmoud Ramy A, Marino Michael F III, McCoy Sherilyn S, Melnyk Peter M., Miller Peter K, O'Neil Robert P, PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pickering Larry G, Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, Scodari Joseph C, Shah Pritesh, TKWD Ventures LLC, Tamaroff Joshua Alexander, VERNON W ANTHONY, Venkataraman Sriram, Volati Ltd, WFD Ventures Fund II, L.P., WFD Ventures LLC, Wyss Hansjoerg, . Peers are determined by cross-linking the filings of GROENHUYSEN WILHELMUS CM with insider filings of others at the same companies.

Related News Stories

Buy The Dip In NovoCure

2018-08-01 seekingalpha
Figure 1: For prudent investors with cash on the sidelines, dips can be the most exciting action in stock prices. (0-1)

NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%

2018-07-17 zacks
NovoCure Limited (NVCR - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 11.1% in the past one-month time frame.

Trade of the Day: Novocure Ltd (NVCR) | InvestorPlace

2018-07-06 investorplace
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today. (14-1)

Under Armour Is A Winner - Cramer's Lightning Round (6/20/18)

2018-06-21 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, June 20. (55-0)

Cramer's lightning round: My favorite cybersecurity stocks

2018-06-20 cnbc
FireEye Inc.: "FireEye is good. I mean, let's go over the pecking order. I think that Proofpoint is better. I think that Palo Alto Networks – how about that huge insider buy by [new CEO] Nikesh Arora? And then, I have to tell you, I like Nice more, I like Foritnet more, I like Cyberark more and then I will endorse FireEye." (39-1)